Keryx Biopharmaceuticals to Present at the 31st Annual J.P. Morgan Healthcare Conference

Keryx Biopharmaceuticals to Present at the 31st Annual J.P. Morgan Healthcare
                                  Conference

Presentation Scheduled for Thursday, January 10th at 9:00 AM PST

PR Newswire

NEW YORK, Jan. 7, 2013

NEW YORK, Jan. 7, 2013 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq:
KERX) today announced that Ron Bentsur, the Company's Chief Executive Officer,
will be presenting at the 31^st Annual J.P. Morgan Healthcare Conference,
being held January 7-10, 2013, in San Francisco, CA. Mr. Bentsur's
presentation is scheduled to take place on Thursday, January 10^th, at 9:00 AM
Pacific Standard Time (12:00 PM EST).

A live audio webcast of Mr. Bentsur's presentation will be accessible from the
Investor Information page of the Company's Website at
http://investors.keryx.com. An archived version of the webcast will be
available following the conclusion of the live presentation.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticalsis focused on the acquisition, development and
commercialization of medically important pharmaceutical products for the
treatment of renal disease. Keryx is developing Zerenex (ferric citrate), an
oral, ferric iron-based compound that has the capacity to bind to phosphate
and form non-absorbable complexes. The U.S.-based Phase 3 clinical program of
Zerenex for the treatment of hyperphosphatemia (elevated phosphate levels) in
patients with end-stage renal disease is being conducted pursuant to a Special
Protocol Assessment (SPA) agreement with the FDA. Zerenex is also in Phase 2
development for the management of phosphorus and iron deficiency in anemic
patients with Stage 3 to 5 non-dialysis dependent chronic kidney disease. In
addition, Keryx's Japanese partner, Japan Tobacco Inc. and Torii
Pharmaceutical Co., Ltd. has filed its New Drug Application for marketing
approval of ferric citrate in Japan for the treatment of hyperphosphatemia in
patients with chronic kidney disease. Keryx is headquartered in New York
City.

KERYX CONTACT:
Lauren Fischer
Director - Investor Relations
Keryx Biopharmaceuticals, Inc.
Tel: 212.531.5965
E-mail: lfischer@keryx.com

SOURCE Keryx Biopharmaceuticals, Inc.

Website: http://investors.keryx.com
 
Press spacebar to pause and continue. Press esc to stop.